SGMT
Sagimet Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.86
+10.47%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$8.20
From 52W high−20.68%
Volume1.68M
Market cap$628.25M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$8.20
From 52W high
−20.68%
Volume
1.68M
Market cap
$628.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.8x
P/E (TTM)
—
RSI (14)
44.7
MomentumView details →
1D Return
+10.47%
YTD Return
+46.03%
SummaryUpdated Jun 1, 2026
Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Mateo, California. Originally incorporated as 3-V Biosciences, Inc., the company changed its name to Sagimet Biosciences in August 2019 and went public in July 2023. The company specializes in developing innovative therapeutics that target fatty acid synthase (FASN) inhibitors to treat diseases caused by dysfunctional lipid metabolism pathways, representing a novel approach in addressing metabolic disorders and certain cancers.
Similar companies
Latest newsMore news →
Sagimet announced that positive 52-week results and mechanistic data from Ascletis' Phase 3 ASC40-304 open-label extension trial of denifanstat in acne will be presented at the 2026 Fall Clinical Dermatology Conference.11d agoSagimet Biosciences priced an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants for 2,750,010 shares, expecting gross proceeds of approximately $115.0 million.20d agoSagimet Biosciences announced positive 52-week results from license partner Ascletis BioScience's Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne vulgaris, presented at EADV 2026.20d ago